<?xml version="1.0" encoding="utf-8"?>
<?xml-stylesheet type="text/xsl" href="http://medicalxpress.com/tmpl/default/css/default/feedRSS.xsl"?>
<rss version="2.0" 
	xmlns:media="http://search.yahoo.com/mrss/">
<channel>
<title>Medical Xpress: PHYSorg news tagged with: metastatic colorectal cancer</title>
<link>http://medicalxpress.com/</link>
<language>en-us</language> 
<description>Medical Xpress internet news portal provides the latest news on Health and Medicine.</description>

 <item>
     <title>Physical activity cuts mortality in colorectal cancer survivors</title>
   	 <description>(HealthDay)—For patients with invasive, non-metastatic colorectal cancer, increased recreational physical activity is associated with reduced all-cause mortality, while prolonged sedentary time correlates with increased all-cause mortality, according to a study published online Jan. 22 in the Journal of Clinical Oncology.</description>
     <link>http://medicalxpress.com/news/2013-01-physical-mortality-colorectal-cancer-survivors.html</link>
	 <category>Cancer</category>
	 <pubDate>Wed, 23 Jan 2013 15:40:01 EST</pubDate>
	 <guid isPermaLink="false">news278176951</guid>
	 <media:thumbnail url="http://s.ph-cdn.com/newman/gfx/news/tmb/2013/physicalacti.jpg" width="90" height="90" />
</item>
<item>
     <title>KRAS and BRAF mutation screening in metastatic colorectal cancer costly in relation to benefits</title>
   	 <description>Researchers report that screening for KRAS and BRAF mutations can reduce the cost of anti-EGFR treatment for metastatic colorectal cancer but with a very small reduction in overall survival according to a new study published on November 28 in the Journal of the National Cancer Institute.</description>
     <link>http://medicalxpress.com/news/2012-11-kras-braf-mutation-screening-metastatic.html</link>
	 <category>Cancer</category>
	 <pubDate>Wed, 28 Nov 2012 16:29:31 EST</pubDate>
	 <guid isPermaLink="false">news273342562</guid>
	 
</item>
<item>
     <title>Dose-escalated cetuximab tolerated in colorectal cancer</title>
   	 <description>(HealthDay) -- For patients with irinotecan-refractory metastatic colorectal cancer (CRC), dose escalation of cetuximab is well tolerated and may improve response and disease control rates, but patients experience more grade &amp;#8805;2 skin reactions, according to a study published online July 2 in the Journal of Clinical Oncology.</description>
     <link>http://medicalxpress.com/news/2012-07-dose-escalated-cetuximab-tolerated-colorectal-cancer.html</link>
	 <category>Cancer</category>
	 <pubDate>Thu, 05 Jul 2012 16:50:20 EST</pubDate>
	 <guid isPermaLink="false">news260725812</guid>
	 <media:thumbnail url="http://s.ph-cdn.com/newman/gfx/news/tmb/2012/doseescalate.jpg" width="90" height="90" />
</item>


</channel>
</rss>
